NEW YORK, Nov. 28 – Biotechnology company Pluvita has signed a three-year, non-exclusive deal for access to AxCell Bioscience’s ProChart database, which contains information on signal transduction pathways in the human proteome, AxCell said Wednesday.
Financial terms of the deal were not disclosed.
The database includes the map of the WW protein domain family, a complete human domain family involved in signal transduction. ProChart also includes protein pathway information from several other domain families, such as PDZ, SH2 and SH3.
"AxCell Biosciences' ProChart database represents a critical addition to Pluvita's drug discovery efforts by enabling us to expand our unique approach to target and lead identification and optimization," Gary Kurtzman, CEO of Pluvita, said in a statement.
Pluvita of Bethesda, Md., said it would use the database in a number of its research and drug discovery initiatives, in areas such as cancer, reproductive health, and diabetes.
ProChart was launched in June as part of Informax’s GenoMax bioinformatics system.
AxCell Biosciences of Princeton, NJ, is a subsidiary of Cytogen.